Research & Development
Infinity BiologiX wins CDC contract to sequence variants of COVID-19 Virus in response to global public health
14 April 2021 -

Central laboratory Infinity BiologiX on Tuesday announced an agreement from the Centers for Disease Control and Prevention (CDC) "Genomic Surveillance for SARS-CoV-2 Variants" to provide genomic sequencing and new variant identification of samples of SARS-CoV-2.

The agreement allows IBX to sequence the viral genomes of random, de-identified samples in the US that test positive in the course of providing molecular diagnostic testing for SARS-CoV-2 for providers and patients.

In conjunction with the agreement, IBX will provide the CDC with completed whole viral sequences in order to aid the CDC in its large-scale longitudinal genomic survey of the virus. The CDC's survey expects to provide baseline information for national and state-level surveillance, identify new variants and ultimately improve the public health response in the US.

In May 2020, IBX was the first company to utilize saliva as the primary biomaterial for SARS-CoV-2 under FDA emergency use authorization, the first to offer an at-home collection as well as performed seven million diagnostic tests across its two sites in NJ and MN.